<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HEPATITIS B IMMUNE GLOBULIN</span><br/>(hep'a-ti-tis)<br/><span class="topboxtradename">H-BIG, </span><span class="topboxtradename">Hep-B-Gammagee, </span><span class="topboxtradename">HyperHep<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">vaccine</span><br/><b>Prototype: </b>Hepatitis B vaccine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mL, 4 mL, 5 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Sterile solution of immunoglobulins [immunoglobulin G (IgG)] prepared by a special process using pooled human plasma. Serum
         has also been tested for and found free of antibody to HIV. The possibility of transmission of hepatitis infection or AIDS
         from H-BIG is remote.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Preparation contains a high antibody titer specific to hepatitis B surface antigen (anti-HBs); plasma does not show serologic
         evidence of hepatitis B surface antigen (HBsAg).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylactically to provide passive immunity to hepatitis B infection in individuals exposed to HBV or HBsAg-positive materials
         (blood plasma, serum). Also as postexposure prophylaxis after bite or percutaneous exposure, ingestion, direct mucous membrane
         contact, sexual or intimate contact, and in neonates born to HBsAg-positive women.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of systemic allergic reactions to immune globulin, concurrent administration of immunosuppression drugs; thrombocytopenia
         or bleeding disorders, HBsAg-positive individuals, patients with specific immunoglobulin A (IgA) deficiency; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hepatitis B Prophylaxis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IM</span> 0.06 mL/kg as soon as possible after exposure, preferably within 24 h, but no later than 7 d, repeat 2830 d after exposure<br/><br/><span class="indicationtitle">Newborn Exposure</span><br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 0.5 mL as soon as possible after birth, but no later than 24 h, repeat dose 3 and 6 mo later<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give Hepatitis B immune globulin at the same time or up to 1 mo preceding hepatitis B vaccination (hepatitis B vaccine) does
            not impair the active immune response from the vaccination.
         </li>
<li>Give preferably into deltoid muscle or anterolateral aspect of thigh.</li>
<li> 				Note: For neonates and small children the preferred injection site is the anterolateral aspect of the thigh. 			</li>
<li> <small>DO NOT</small> administer by IV; inadvertent IV or intravascular administration can cause a precipitous fall in BP and an anaphylactic reaction.
         </li>
<li>Store at 2°8° C (36°46° F) unless otherwise directed. Avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Muscle stiffness; pain, tenderness, swelling, erythema of injection site, nausea, faintness, fever, dizziness, malaise, lassitude,
      body and joint pain, leg cramps. <span class="typehead">Skin:</span> Urticaria, rash, angioedema, pruritus, erythema, sensitization (following large or repeated doses), anaphylaxis (rare). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May interfere with immune response to <span class="classification">live-virus vaccines</span> (measles/mumps/rubella/poliovirus). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from IM site. <span class="typehead">Onset:</span> 16 d. <span class="typehead">Peak:</span> 311 d. <span class="typehead">Duration:</span> 26 mo. <span class="typehead">Elimination:</span> Half-life 21 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Have epinephrine 1:1000 readily available; hypersensitivity reactions are most likely to occur in patients receiving large
            doses or repeated injections.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn potential adverse reactions.</li>
<li>Do not breast feed after taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>